[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-embolism-diagnosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-embolism-diagnosis":36},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,60,98,127,152,176,212,240,266,291,319,354,384,406],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":37,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100603978","early-exercise-based-rehabilitation-in-patients-hospitalized-for-acute-pulmonary-embolism-100603978",false,"NCT07143539","Early Exercise-Based Rehabilitation in Patients Hospitalized for Acute Pulmonary Embolism","Early Exercise-based Rehabilitation in High-risk Patients Hospitalized for Acute Pulmonary Embolism: a Pragmatic Multicenter Randomized Partially Blinded Superiority Trial","RehabPE","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Hospitalization for objectively confirmed acute symptomatic PE, defined as intraluminal filling defect of a segmental or more proximal pulmonary artery on computed tomography pulmonary angiography (CTPA) or a high-probability ventilation-perfusion scintigraphy, and admission within the past 7 days\n3. Increased risk for post-PE syndrome, defined as simplified Pulmonary Embolism Severity Index (sPESI) ≥1 point at the time of admission\n4. Written informed consent\n\nExclusion Criteria:\n\n1. Contraindication to EBR (known unstable cardiac conditions like angina pectoris, severe valvular heart disease, or severe resting pulmonary hypertension)\n2. Medical condition that clearly precludes participation in EBR (e.g., inability to walk, unstable joints, severe neurological impairment)\n3. Recently completed (i.e., \\\u003C6 months), ongoing, or planned in- or outpatient EBR, or planned supervised outpatient physiotherapy for any indication\n4. Planned hospitalization during follow-up (e.g., elective surgery or inpatient chemotherapy)\n5. Contraindication to anticoagulation\n6. Life expectancy \\\u003C1 year based on the treating physician's clinical judgement\n7. Known pregnancy\n8. Inability to speak German or French\n9. Participation in another study that prohibits concurrent participation in RehabPE\n10. Unable to provide informed consent (e.g., due to dementia)\n11. Unwilling to provide informed consent\n12. Prior enrollment in this study","ALL","18 Years",{"count":20,"type":21},160,"ESTIMATED","INTERVENTIONAL",[24],"NA","Up to half of patients with pulmonary embolism (PE) suffer from impaired quality of life, reduced physical capacity, and symptoms like shortness of breath even three months after diagnosis, despite standard treatment with anticoagulation (blood thinners). The randomized RehabPE trial investigates whether an early, structured rehabilitation program with physical training and patient education can prevent such long-term effects.\n\nThe study includes hospitalized patients with acute symptomatic PE who are at increased risk of impaired quality of life three months after diagnosis. After informed consent, patients are randomly assigned to one of two groups: one receives an early 6-8-week, center-based rehabilitation program; the other receives standard follow-up care without rehabilitation. The intervention group completes 16-18 outpatient sessions of endurance and strength training, along with two education sessions covering the condition, treatment, and symptom management.\n\nOver 180 days, changes in quality of life, physical exercise capacity, breathlessness, and psychological symptoms, and the time to return to work \u002F usual daily activities will be monitored and compared between groups.",[27,28,29,30,31,32,33,34,35,36],"Venous Thromboembolism (VTE)","Exercise Therapy","Quality of Life (QOL)","Anxiety Depression","Humans","Exercise Tolerance","Rehabilitation Exercise","Dyspnea","Functional Status","Pulmonary Embolism (Diagnosis)",[38,39,40,41,42,43,44,45,46],"pulmonary embolism","deep vein thrombosis","excercise-based rehabilitation","post-PE syndrome","health-related quality of life","anxiety","depression","dyspnea","impact of early excercise-based rehabilitation","RECRUITING","2026-06-11",{"date":50,"type":51},"2026-06-12","ACTUAL",{"date":53,"type":51},"2025-12-17",{"date":55,"type":21},"2028-06",{"name":57,"class":58},"Insel Gruppe AG, University Hospital Bern","OTHER",6,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":67,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":68,"targetDuration":4,"studyType":22,"phases":70,"briefSummary":71,"conditions":72,"keywords":82,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100605188","cardiac-point-of-care-ultrasound-training-pathway-for-emergency-department-advanced-practice-providers-100605188","NCT07159269","Cardiac point-of Care Ultrasound Training Pathway for Emergency Department Advanced Practice Providers","Cardiac Point-of-care Ultrasound Clinical Training Pathway Implementation and Impact Assessment for Advanced Practice Providers in the Emergency Department","Inclusion Criteria:\n\n* advanced practice providers (APPs) currently working in our ED, with additional APPs as they are hired (expected to be about 75 APPs total within the next 3 years due to expanding staffing needs and coverage models).\n\nExclusion Criteria:\n\n* non-APPs such as physicians, nurses, or other clinical staff",true,{"count":69,"type":21},75,[24],"The aim of this study is to assess emergency medicine physician and advanced practice provider (APP) knowledge and technical skill in performance of a point-of-care ultrasound simulation and just-in-time training pathway to determine the feasibility, acceptability, and usability of the ultrasound training program. By performing this study, we hope to create a standardized training model which could potentially facilitate point-of-care ultrasound (POCUS) clinical performance and thereby improve patient care.",[73,74,75,36,76,77,78,79,80,81],"Cardiovascular Disease Acute","Emergency Department Patient","Heart Failure Acute","Point of Care Ultrasound (POCUS)","Cardiac Tamponade","Pericardial Effusion","Diagnostic Imaging","Medical Training","Implementation Science",[83,84,85,86,87],"point of care ultrasound","focused cardiac ultrasound","advanced practice provider training","medical education","implementation science","2026-06-01",{"date":90,"type":51},"2026-06-03",{"date":92,"type":51},"2025-11-13",{"date":94,"type":21},"2030-06-30",{"name":96,"class":58},"Duke University",1,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":67,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":108,"conditions":109,"keywords":112,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":123,"leadSponsor":125,"locationsCount":97},"100624652","screening-for-pulmonary-embolism-using-single-channel-electrocardiogram-100624652","NCT07412418","Screening for Pulmonary Embolism Using Single-channel Electrocardiogram","Screening for Pulmonary Embolism Using Single-channel Electrocardiogram Data Using Machine Learning Models","Inclusion Criteria:\n\n1. A clinical condition requiring exclusion of acute pulmonary embolism;\n2. The presence of written informed consent of the patient to participate in the study;\n3. Age from 18 years old and older\n\nNon-inclusion criteria:\n\n1. Refusal to undergo examination or the inability to reliably verify or exclude the diagnosis of pulmonary embolism;\n2. Treatment, in particular anticoagulant therapy, before recording a single-lead ECG;\n3. Conditions in which recording an ECG in lead I is not possible (congenital anomalies of the upper limbs, traumatic amputation of the upper limbs, tremor, etc.);\n4. Refusal to sign written informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Poor ECG quality, preventing the necessary analysis of a single-channel ECG;\n2. Incomplete examination, preventing a reliable determination of the presence or absence of pulmonary embolism;\n3. Refusal to further participate in the study.",{"count":106,"type":21},500,"OBSERVATIONAL","It is a prospective, controlled, single-center, observational, non-randomized study. The study is planned to include at least 500 patients 18 years old and older (300 patients in the training sample and 200 patients in the test sample.\n\nThe study will include all patients requiring exclusion of the diagnosis of acute pulmonary embolism. Patients will be examined according to clinical guidelines to confirm the diagnosis of pulmonary embolism (laboratory, clinical and instrumental).\n\nDuring the course of the study, the authors of the work do not interfere with the scope of the examination, which is caried out on patients in accordance with clinical guidelines.\n\nAll patients included in the study will undergo electrocardiogramm (ECG) in standart lead I for 1 minute, followed by spectral analysis of the obtained data, which will be stored at the Remote monitoring center of Sechenov University without being linked to the personal data of patients. A spectral analysis of the electrocardiogram will be performed using a continuous wavelet transformation. The result of this study will be the identification of ECG parameters that will correlate with pulmonary embolism.",[36,110,111],"Respiratory Failure With Hypoxia","Chronic Obstructive Pulmonary Disease (COPD)",[113,114,115,38,116,117],"Screening","single-channel electrocardiogram","machine learning models","respiratory failure","chronic obstructive pulmonary disease","NOT_YET_RECRUITING","2026-04-30",{"date":121,"type":51},"2026-05-01",{"date":121,"type":21},{"date":124,"type":21},"2028-07-30",{"name":126,"class":58},"I.M. Sechenov First Moscow State Medical University",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":148,"leadSponsor":150,"locationsCount":4},"100636023","3d-eit-for-diagnosis-and-monitoring-of-pulmonary-embolism-100636023","NCT07560293","3D-EIT for Diagnosis and Monitoring of Pulmonary Embolism","Prospective Validation of Three-Dimensional Electrical Impedance Tomography for the Diagnosis, Risk Stratification, and Longitudinal Monitoring of Pulmonary Embolism","TIDE-PE","Inclusion Criteria:\n\n* Age 18 years or older\n* Body mass index (BMI) less than 50 kg\u002Fm²\n* Able to provide written informed consent\n* first episode of pulmonary embolism confirmed by CT pulmonary angiography (CTPA), with or without CT venography (CTV)\n\nExclusion Criteria:\n\n* Previous diagnosis of pulmonary embolism\n* Pregnancy\n* Thoracic deformity or chest wall abnormality preventing proper placement of the EIT electrode belt\n* Contraindications to EIT use, including implantable cardioverter-defibrillator, pacemaker, implanted pumps, or chest wounds limiting electrode placement\n* Concurrent participation in another interventional clinical study Hemodynamic instability requiring emergency intervention that precludes completion of the EIT examination (PE cohort only)\n* Any other condition judged by the investigator to make the participant unsuitable for study participation",{"count":136,"type":21},115,"This prospective observational study aims to validate three-dimensional electrical impedance tomography (3D-EIT) as a non-invasive bedside tool for the diagnosis and longitudinal monitoring of pulmonary embolism (PE). The study will include a PE cohort and a control cohort without PE or venous thromboembolism (VTE). Using algorithms that separate ventilation and perfusion signals, 3D-EIT-derived indices, including the Matching Index (MI), Dead Space Index (DI), and Shunt Index (SI), will be quantified. The diagnostic performance of MI and DI will be evaluated against computed tomography pulmonary angiography (CTPA), and their associations with PE severity, risk stratification, and treatment response will be explored. This study is expected to support the clinical translation of 3D-EIT as a radiation-free bedside functional imaging tool for PE management.",[36,27],[140,141,142,143,144],"Pulmonary Embolism","Electrical Impedance Tomography","Three-dimensional Imaging","Lung Perfusion","Ventilation-Perfusion Mismatch","2026-04-24",{"date":121,"type":51},{"date":121,"type":21},{"date":149,"type":21},"2028-05-01",{"name":151,"class":58},"Beijing Tsinghua Chang Gung Hospital",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":17,"minAge":158,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":97},"100633471","role-of-n-on-contrast-chest-ct-ncct-based-ct-v-q-in-patients-with-acute-pulmonary-embolism-ape-100633471","NCT07527117","Role of n On-contrast Chest CT (NCCT) Based CT V: Q in Patients With Acute Pulmonary Embolism (aPE)","Inclusion Criteria:\n\n1. Patients undergoing CTPA for suspected aPE\n2. Patients who provide written informed consent to participate\n3. Adults patients \\>\u002F= 21 years of age\n4. Mini Mental State Exam (MMSE) score of 18 or more.\n\nExclusion Criteria:\n\n1. Patients who decline informed consent\n2. Patients with known chronic PE\n3. Patients with known interstitial lung diseases\n4. Patients who cannot raise their arms above their shoulders (arms can cause serious artifacts)\n5. Women of child-bearing potential (\\\u003C 55 years) who test positive for pregnancy test\n6. Patients \\\u003C 21 years of age (to avoid research radiation dose in young patients)\n7. Patients with any EMR documented cognitive impairment or diseases such as dementia, recent head injury, psychiatric disorders, or other neurological diseases that impair decision-making.\n8. Pregnant subjects\n9. Women of child-bearing potential (21-55 years) who refuse to take a urine pregnancy test prior to their CT examination\n10. Mini Mental State Exam (MMSE) score of less than 18.","21 Years",{"count":160,"type":21},750,[24],"We are doing the research to see if a CT scan without the dye can help find pulmonary emboli. If you agree to join the study, you will be asked to sign this consent form before we do any research procedures. If you join the research, we will ask you to blow into a small device known as a spirometer to train you to hold your breath after you inhale and exhale. Spirometer is a small handheld device to find out how well your lungs work when you inhale and exhale. For this research, we will obtain two extra sets of CT images at very low levels of radiation dose. The two extra sets of images will take less than 1 minute. Your total participation time is about 5 minutes. We will also review your medical record for up to 30 to 90 days after your CT scan.\n\nThe main risks of being in the study are exposure to ionizing radiation which may have health risks, and minor inconvenience from the spirometer test.\n\nYou will not benefit from taking part in this research study. If you take part in this study, your participation may help people in the future. If you decide not to be in the study, you will still have the standard-of-care chest CT with the dye ordered by your doctor. You will not be paid for taking part in this research study.",[36,164],"Pulmonary Embolism Acute",[166],"CT ventilation perfusion pulmonary embolism CT pulmonary angiogram","2026-04-07",{"date":169,"type":51},"2026-04-14",{"date":171,"type":21},"2026-07-01",{"date":173,"type":21},"2028-12-31",{"name":175,"class":58},"Massachusetts General Hospital",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":186,"conditions":187,"keywords":191,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":211},"100630701","repeated-examinations-for-typing-pulmonary-embolism-100630701","NCT07491094","Repeated Examinations for Typing Pulmonary Embolism","Repeated Examinations for Typing Pulmonary Embolism (RE-TyPE)","RE-TyPE","Inclusion Criteria:\n\n1. Adult patients (≥ 18 years old) who is diagnosed with, or followed as out-patients for, PE at Sahlgrenska University Hospital\n2. Written informed consent\n\nExclusion Criteria from Cohort A:\n\n1. Low risk, intermediate-low risk or high risk PE\\*\n2. \\>48 hours since arrival to hospital\n3. Expected inability to comply with the protocol (e.g. dementia)\n\nThere are no exclusion criteria from Cohort B. Patients in Cohort B who are not part of Cohort A may be included at diagnosis (day 0) or at follow-up (\\~day 90).\n\n\\*If biomarkers (and\u002For echocardiography) are not available in hemodynamically stable patients, RV\u002FLV-ratio \\>1 will be considered as preliminary intermediate-high risk. If biomarkers later fall out negative, the patient will be considered as intermediate-low risk and will be moved to Cohort B",{"count":185,"type":21},400,"PURPOSE\n\nThe two related purposes of the RE-TyPE study are:\n\n1. To improve understanding of the early clinical course of intermediate-high risk pulmonary embolism and its association with outcome and\n2. To establish a platform for longitudinal follow-up for all pulmonary embolism at Sahlgrenska University Hospital\n\nHYPOTHESES\n\n1. The dynamic pattern of change, evaluated thorough repeated measures of biomarkers, electrocardiography and echocardiography during the first 48 hours after pulmonary embolism, better predicts outcome than static measurements currently used to predict outcome\n2. Establishment of a platform for longitudinal follow-up will improve quality of care and outcome for patients with pulmonary embolism at Sahlgrenska University Hospital",[36,164,188,189,190],"Pulmonary Embolism With Acute Cor Pulmonale","Pulmonary Embolism With Right Ventricle Enlargement","Pulmonary Embolism (PE)",[192,193,194,195,196,197,198,199,200,201],"Echocardiography","Point Of Care UltraSound (POCUS)","Electrocardiography (ECG)","Biomarkers\u002FBlood","Troponin I","NT-pro-BNP","Lactate","Prediction model","Clinical deterioration","Death","2026-04-02",{"date":204,"type":51},"2026-04-06",{"date":206,"type":51},"2026-04-01",{"date":208,"type":21},"2032-01-01",{"name":210,"class":58},"Sahlgrenska University Hospital",3,{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":22,"phases":222,"briefSummary":223,"conditions":224,"keywords":227,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":239},"100631360","pulmonary-embolism-in-patients-with-acute-heart-failure-pehf-study-100631360","NCT07499661","Pulmonary Embolism in Patients With Acute Heart Failure (PEHF Study)","Pulmonary Embolism in Patients With Acute Heart Failure: A Pragmatic Cluster-Randomized Trial (PEHF Study)","PEHF","Inclusion Criteria:\n\n* Adult patient (≥18 years)\n* Admission to the emergency department or cardiology unit of a participating center\n* Recent onset or worsening dyspnea and\u002For orthopnea\n* Diagnosis of acute heart failure defined by recent dyspnea associated with at least one of the following:\n\n  * Bilateral pulmonary crackles on auscultation and\u002For peripheral edema\n  * Signs of pulmonary congestion on chest X-ray or lung\u002Fcardiac ultrasound\n  * Elevated natriuretic peptide levels (BNP or NT-proBNP)\n  * Documented history of heart failure (known chronic heart failure or prior hospitalization for acute heart failure)\n* Patient affiliated with or beneficiary of a social security system\n* Patient able and willing to provide free, informed, and written consent\n\nExclusion Criteria:\n\n* Shock state suggesting cardiogenic shock and\u002For severe pulmonary embolism\n* Severe respiratory distress at inclusion preventing appropriate positioning or performance of imaging examinations\n* Evidence of acute coronary syndrome on electrocardiogram at admission\n* Severe renal impairment (creatinine clearance \\\u003C30 mL\u002Fmin)\n* Known hypersensitivity or allergy to iodinated contrast agents\n* Ongoing therapeutic anticoagulation for more than 48 hours prior to admission\n* Hospitalization for more than 48 hours prior to inclusion\n* Inability to ensure 90-day follow-up (e.g., end-of-life situation, no fixed address, patient not reachable)\n* Inadequate understanding of the French language preventing proper study information and consent\n* Pregnant, breastfeeding, or postpartum women\n* Individuals under legal protection or other vulnerable populations, including minors and protected adults, in accordance with applicable public health regulations (Articles L.1121-5 to L.1121-8 and L.1122-1-2 of the French Public Health Code)",{"count":221,"type":21},740,[24],"This study focuses on two serious and common medical conditions: heart failure and pulmonary embolism (a blood clot in the lungs). Heart failure happens when the heart cannot pump blood effectively, and it is one of the main reasons older adults are admitted to the hospital. Pulmonary embolism can be life-threatening and may worsen heart failure or even trigger it.\n\nDoctors believe that pulmonary embolism may often go undetected in patients who come to the hospital with symptoms of acute heart failure, such as sudden shortness of breath. This is because both conditions can cause similar symptoms, making it difficult to tell them apart. As a result, doctors may sometimes assume the symptoms are only due to heart failure and not investigate further for a possible blood clot.\n\nHowever, missing a pulmonary embolism can have serious consequences. Studies suggest that some patients with heart failure who die may actually have had an undiagnosed pulmonary embolism. Current medical guidelines recommend checking for pulmonary embolism when the cause of breathing problems is unclear, but in real-life practice, this is not always done.\n\nThe goal of this study is to find out whether pulmonary embolism is underdiagnosed in patients with suspected acute heart failure and whether systematically testing for it could improve patient outcomes.\n\nTo do this, the study will compare two approaches in several hospitals. In half of the hospitals, doctors will follow their usual practice and decide case by case whether to test for pulmonary embolism. In the other half, doctors will systematically test all eligible patients for pulmonary embolism using recommended diagnostic methods.\n\nAdult patients admitted with recent or worsening breathing difficulties and signs of acute heart failure may be included in the study, provided they give their consent. Researchers will collect information about their symptoms, tests, diagnosis, and treatments.\n\nPatients will be monitored during their hospital stay and for three months afterward. The study will track important outcomes such as survival, new blood clots, bleeding events, repeated hospital visits for breathing problems, and overall time spent in the hospital.\n\nThe researchers expect to include about 740 patients in total. They estimate that pulmonary embolism may be found in about 1% of patients with usual care, but up to 5% when doctors systematically look for it.\n\nThis study aims to better understand how often pulmonary embolism occurs in patients with acute heart failure and whether more systematic testing could lead to earlier diagnosis and better care. The results could help improve medical practice and reduce complications or deaths related to missed diagnoses.",[225,36,226],"Acute Heart Failure (AHF)","Venous Thromboembolism",[228],"Cluster-randomized trial","2026-03-30",{"date":231,"type":51},"2026-04-03",{"date":233,"type":21},"2026-06",{"date":235,"type":21},"2028-09",{"name":237,"class":238},"University Hospital, Angers","OTHER_GOV",10,{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":250,"conditions":251,"keywords":254,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":262,"leadSponsor":264,"locationsCount":4},"100629331","incidence-and-characteristic-of-crt-persistent-after-catheter-extraction-in-icu-patients-100629331","NCT07473284","Incidence and Characteristic of CRT Persistent After Catheter Extraction in ICU Patients","Incidence and Characteristics of Venous Catheter-related Thrombosis Persisting After Catheter Removal in Intensive Care Unit Patients.","CRT-PERSIST","Inclusion Criteria:\n\n* age over 18 years\n* ICU hospitalization\n* signed informed consent\n* an indwelling central venous catheter planned for extraction\n\nExclusion Criteria:\n\n* age under 18 years\n* local pathology precluding ultrasound examination\n* disagreement with participation in the study",{"count":249,"type":21},300,"The goal of this observational study is to describe characteristics of catheter related thrombosis (CRT) that persists after catheter extraction in condition of intensive care unit. The main questions it aims to answer are:\n\n1. What is the incidence of CRT that persists after catheter extraction in patients hospitalized in the intensive care unit?\n2. What are the risk factors for this phenomenon?\n3. What is the fate of such a thrombus, including recanalization or the development of complications such as pulmonary embolism or post-thrombotic syndrome?",[252,253,36],"Catheter Thrombosis","Post Thrombotic Syndrome",[255,256,257],"CRT","Persistent thrombosis","Thrombotic complication","2026-03-10",{"date":260,"type":51},"2026-03-16",{"date":206,"type":21},{"date":263,"type":21},"2028-01-01",{"name":265,"class":58},"Masarykova Nemocnice v Usti nad Labem, Krajska Zdravotni a.s.",{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":274,"conditions":275,"keywords":276,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":290},"100626520","optimal-time-for-reperfusion-in-acute-pulmonary-embolism-100626520","NCT07436702","Optimal Time for Reperfusion in Acute Pulmonary Embolism","OPTIRAPE","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patients with a diagnosis of intermediate-high or high pulmonary embolism confirmed by computed tomography pulmonary angiography (CTPA), pulmonary angiography, or echocardiography (evidence of a floating thrombus in the right atrium or right ventricle, or proximal visualization of thrombus in the pulmonary artery).\n* Classified as high-risk or intermediate-high-risk according to the 2019 European Society of Cardiology guidelines.\n* Provision of informed consent for the processing of personal data.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Patients in whom a diagnosis of acute high-risk or intermediate-high-risk pulmonary embolism has been excluded.\n* Inability to provide informed consent.",{"count":106,"type":21},"Pulmonary embolism (PE) is the third leading cause of cardiovascular mortality worldwide. Current guidelines recommend early reperfusion for high-risk and intermediate-high-risk PE, yet systemic thrombolysis and percutaneous therapies are frequently underutilized, and no specific timing for reperfusion is defined, unlike in acute myocardial infarction or ischemic stroke. As most PE-related in-hospital deaths occur within the first hours and thrombus composition changes over time, defining an optimal reperfusion time window may improve survival and prevent hemodynamic deterioration. We therefore propose a national, multicenter, prospective observational study to evaluate the prognostic impact of reperfusion timing, using systemic thrombolysis or catheter-directed therapies, on in-hospital mortality and haemorrhagic or cardiovascular complications.",[36,164],[277,278,279,280],"Fibrinolysis","Anticoagulation","Catheter-directed treatments","Time of Reperfusion","2026-03-01",{"date":283,"type":51},"2026-03-03",{"date":285,"type":51},"2025-11-25",{"date":287,"type":21},"2026-10-30",{"name":289,"class":58},"Azienda ULSS 8 Berica",7,{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":297,"eligibilityCriteria":298,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":22,"phases":301,"briefSummary":302,"conditions":303,"keywords":304,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":318},"100626099","inorganic-nitrates-in-intermediate-high-risk-pulmonary-embolism-100626099","NCT07431229","Inorganic Nitrates in Intermediate High-risk Pulmonary Embolism","Inorganic Nitrates in Pulmonary Embolism With Hemodynamic Instability","NITRATE-PE","Inclusion Criteria:\n\nAcute PE with symptoms \\\u003C 14 days confirmed by computer tomography (CT) AND RV dilatation on CT or ECHO AND Troponin T \\> 45 pg\u002Fml\n\nExclusion Criteria:\n\nCardiac arrest with cardiopulmonary resuscitation, Thrombolysis or endovascular thrombectomy, \\\u003C 18 years of age, Pregnancy, INR \\> 2,5 or platelet count \\\u003C 100, DAPT or OAK, Inability to give informed consent to the study, Contraindications for right heart catheterization: mechanical devices, endocarditis, GUCH-patients, Short expected lifespan \\\u003C 120 days \u002F withdrawal of care, Imdur or other medications with nitrates, Daily usage of mouth wash prescribed by dentist or doctor",{"count":300,"type":21},36,[24],"Pulmonary embolism (PE) is a serious condition caused by blood clots blocking the blood vessels in the lungs. In some patients, PE leads to increased pressure in the lung circulation and strain on the right side of the heart. Patients with intermediate high-risk PE have signs of right heart stress and heart muscle injury and are at risk of clinical deterioration despite standard treatment with anticoagulation.\n\nIn addition to the mechanical obstruction caused by blood clots, pulmonary embolism also causes narrowing of the lung blood vessels due to vasoconstriction. This increases pulmonary vascular resistance and contributes to elevated pressure in the pulmonary arteries, which can worsen right heart function. Treatments that reduce pulmonary artery pressure and vascular resistance could therefore potentially improve heart function and stabilize patients in the acute phase of PE. However, there is limited clinical evidence regarding the safety and effectiveness of pulmonary vasodilator therapy in this patient group.\n\nInorganic nitrates, found naturally in foods such as beetroot, are converted in the body to nitric oxide, a substance that relaxes blood vessels. Inorganic nitrates have been shown to lower blood pressure and improve pulmonary hemodynamics in other cardiovascular conditions, and are generally considered safe. Their effects in patients with intermediate high-risk pulmonary embolism have not previously been studied in a randomized controlled trial.\n\nThe aim of this study is twofold: first, to describe invasive hemodynamic measurements in patients with intermediate high-risk pulmonary embolism using right heart catheterization; and second, to investigate the safety, feasibility, and physiological effects of treatment with oral inorganic nitrate compared with placebo.\n\nThis is a multicenter, double-blind, randomized controlled trial conducted at two hospitals in Sweden. Adult patients with confirmed acute pulmonary embolism, right ventricular dilation, and elevated cardiac troponin levels will be included after providing informed consent. All patients will receive standard care, including anticoagulation therapy. In addition, all participants will undergo right heart catheterization to measure pressures and blood flow in the heart and lungs.\n\nParticipants will be randomly assigned to receive either nitrate-rich beetroot juice or a placebo beetroot juice for five days. Neither the patients nor the treating clinicians or investigators will know which treatment is given. The primary outcome is mean pulmonary artery pressure measured three hours after administration of the study treatment. Secondary outcomes include additional hemodynamic measurements, blood biomarkers, and safety outcomes such as low blood pressure or need for vasopressor treatment.\n\nThe results of this study will improve understanding of pulmonary hemodynamics in intermediate high-risk pulmonary embolism and help determine whether inorganic nitrate therapy is safe and has beneficial physiological effects in this patient population.",[36],[305,306,307,308],"Pulmonary embolism","Pulmonary vasodilation","Invasive hemodynamics","right heart catheterization","2026-02-18",{"date":311,"type":51},"2026-02-24",{"date":313,"type":51},"2026-02-17",{"date":315,"type":21},"2028-02-25",{"name":317,"class":58},"Karolinska Institutet",2,{"id":320,"slug":321,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":325,"eligibilityCriteria":326,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":327,"enrollmentInfo":328,"targetDuration":4,"studyType":22,"phases":329,"briefSummary":330,"conditions":331,"keywords":342,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":352,"locationsCount":97},"100609205","intraoperative-paravertebral-block-and-postoperative-complications-100609205","NCT07211529","Intraoperative Paravertebral Block and Postoperative Complications","Perioperative Paravertebral Block Reduces Postoperative Complications in Thoracic Surgery: An Observational Study","IPVB and POCs","Inclusion Criteria:\n\n1. Male or female participants aged 18 years or older.\n2. Scheduled to undergo thoracic surgery via Video-Assisted Thoracoscopic Surgery (VATS) or Robotic-Assisted Thoracoscopic Surgery (RATS), including wedge resection, segmentectomy, lobectomy, or mediastinal surgery.\n3. Signed informed consent obtained prior to study participation. -\n\nExclusion Criteria:\n\n1. Patients who refuse to provide informed consent.\n2. Anesthesiologists who have not received training in ultrasound-guided paravertebral block (PVB-US).\n3. History of ipsilateral thoracic surgery.\n4. Conversion to open thoracotomy during the procedure.\n5. Patients who did not complete the scheduled surgery due to disease progression or medical reasons.\n6. Patients who are lost to follow-up or refuse postoperative follow-up. -","80 Years",{"count":106,"type":21},[24],"This study aims to evaluate the clinical association between intraoperative paravertebral block and the reduction of postoperative complications following thoracic surgery.",[332,333,334,335,336,337,338,339,36,340,341],"Video-assisted Thoracoscopic Surgery (VATS)","Lung Cancer (Diagnosis)","Pulmonary Infections","Respiratory Failure Without Hypercapnia","Pleural Effusion Due to Another Disorder (Disorder)","Atelectasis","Bronchospasm","Pneumothorax","Bronchopleural Fistula","Acute Respiratory Distress Syndrome (ARDS)",[343,344,345],"Paravertebral Block (PVB)","Video-Assisted Thoracoscopic Surgery (VATS)","Postoperative Complications","2025-09-30",{"date":348,"type":51},"2025-10-08",{"date":350,"type":51},"2025-03-25",{"date":173,"type":21},{"name":353,"class":58},"Tongji Hospital",{"id":355,"slug":356,"hasResults":11,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":11,"sex":17,"minAge":362,"maxAge":4,"enrollmentInfo":363,"targetDuration":365,"studyType":107,"phases":4,"briefSummary":366,"conditions":367,"keywords":371,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":97},"100589462","china-pulmonary-vascular-disease-intervention-diagnosis-and-management-study-right-heart-catheterization-100589462","NCT06954727","China Pulmonary Vascular Disease Intervention Diagnosis and Management Study-right Heart Catheterization","China Pulmonary Vascular Disease Intervention Diagnosis and Management Study-A Quality Control on Right Heart Catheterization","CHA-RHC","Inclusion Criteria:\n\n* Patients who underwent right heart catheterization for the first time due to dyspnea or suspected pulmonary hypertension\n* Age ≥14 years old\n\nExclusion Criteria:\n\n* Vital data missing\n* Did not sign informed consent or did not agree to follow-up","14 Years",{"count":364,"type":21},10000,"1 Year","Right heart catheterization(RHC) plays a crucial role in the diagnosis and treatment of pulmonary vascular diseases(PVD). In China, the lack of equipment and technical expertise has historically limited the implementation of RHC, thereby greatly restricting the diagnosis and treatment of RVD. In recent years, with improvements in these issues, more hospitals have acquired the capability to perform RHC. The purpose of this study is to conduct quality control of RHC across multiple pulmonary hypertension(PH) centers in China. The study population consists of patients who underwent RHC for the first time due to dyspnea or suspected PH. This study retrospectively and prospectively collects multicenter RHC data, with the main quality control contents including indications for the procedure, collection and analysis of hemodynamic data, diagnosis and treatment, and long-term management of patients.",[368,36,369,370],"Pulmonary Hypertension","Pulmonary Arterial Hypertension","Right Heart Catheterization",[308,372,373,374],"pulmonary hypertension","pulmonary arterial hypertension","pulmonary vascular disease","2025-05-16",{"date":377,"type":51},"2025-05-21",{"date":379,"type":51},"2018-01-01",{"date":381,"type":21},"2030-12-31",{"name":383,"class":58},"China-Japan Friendship Hospital",{"id":385,"slug":386,"hasResults":11,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":67,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":391,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":392,"conditions":393,"keywords":394,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":4},"100574214","mangement-of-pulmonary-emboli-100574214","NCT06756373","Mangement of Pulmonary Emboli","Adherence to International Guidelines Directed Risk Stratification and Management of Acute Pulmonary Embolism, an Egyptian Experience","Inclusion Criteria:\n\n* No includion criteria\n\nExclusion Criteria:\n\n* No exclusion criteria",{"count":249,"type":21},"To assess to which extent we are adherent to ESC guidelines 2019 in management of patients presented with acute pulmonary embolism",[36],[395,396],"simplified pulmonary embolism l index","POPE","2025-01-01",{"date":399,"type":51},"2025-01-03",{"date":401,"type":21},"2025-01-20",{"date":403,"type":21},"2027-12-17",{"name":405,"class":58},"Assiut University",{"id":407,"slug":408,"hasResults":11,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":22,"phases":415,"briefSummary":416,"conditions":417,"keywords":420,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":97},"100565950","microvisk-continuous-blood-donation-study-100565950","NCT06648837","Microvisk Continuous Blood Donation Study","Continuous Blood Donation for the Development of the Microvisk PT\u002FINR","Inclusion Criteria:\n\n* Currently undergoing Warfarin therapy.\n* Over 18 years old\n\nExclusion Criteria:\n\nA participant is not eligible for participation if ANY of the following criteria are met:\n\n* Participant is \\\u003C18 years of age\n* Participant is unable to give consent\n* Participant has been treated with Unfractionated Heparin, or Low Molecular Weight Heparin, within the last 7 days\n* Participant has, or is suspected of having, Anti-Phospholipid Syndrome (APS)\n* Participant is pregnant, or has been in the past 12 months\n* Participant is known to have HIV\u002FAIDS, is a carrier of Hepatitis A, B or C, has had tuberculosis or a tropical disease\n* Participant is suspected of intravenous drug use",{"count":414,"type":21},2500,[24],"Microvisk Technologies Ltd designs and develops test systems for monitoring the effectiveness of Warfarin and Warfarin-like medications.\n\nWarfarin and Warfarin-like medications are used to reduce the risk of stroke in people with an irregular heart rhythm (Atrial Fibrillation) or with mechanical heart valve replacements, as well as reducing the risk of recurrent Venous Thromboembolism.\n\nWarfarin dosing needs to be individualized. In order to correctly dose an individual in order to optimize the effectiveness of warfarin, and minimize the risk of bleeding, close monitoring of the degree of anticoagulation is required through regular blood testing. This test is known as PT\u002FINR (Prothrombin Time\u002FInternational Normalised Ratio). Simply, it is the measure of the amount of time (in seconds) it takes for your blood to clot.\n\nMicrovisk Technologies Ltd are developing new anticoagulant test strips for patients on warfarin or warfarin like medications. The blood collected as part of this study will be tested upon Microvisk's second generation Prothrombin\u002FInternational Normalized Ratio (PT\u002FINR) Test System. The donated blood will be used on ongoing development, validation, verification, and calibration projects. This study is being performed in partnership with the Oxford University Hospital (OUH) and Local Clinical Research Networks (LCRN) Thames Valley Core team, part of National Institute for Health and Care Research (NIHR).",[36,418,419],"Deep Vein Thrombosis","Atrial Fibrillation (AF)",[421,422,423,424,425,426],"PT","INR","PT\u002FINR","Warfarin","Vitamin K agonist","POC testing","2024-11-20",{"date":429,"type":51},"2024-11-21",{"date":431,"type":21},"2025-01-13",{"date":433,"type":21},"2029-11-01",{"name":435,"class":436},"Microvisk Technologies Ltd","INDUSTRY"]